Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26269114)

  • 21. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
    Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS
    Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
    Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
    Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
    Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
    Ma F; Sun T; Shi Y; Yu D; Tan W; Yang M; Wu C; Chu D; Sun Y; Xu B; Lin D
    Lung Cancer; 2009 Oct; 66(1):114-9. PubMed ID: 19201048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
    J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
    Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
    Xu CA; Su H; Liu JL; Li L; Zou HW
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
    Liu G; Cheng D; Ding K; Le Maitre A; Liu N; Patel D; Chen Z; Seymour L; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Feb; 7(2):316-22. PubMed ID: 22237259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.
    Tam TC; Ho JC; Wong MK; Wong WM; Wang JK; Lam JC; Lui MM; Lam WK; Ip MS; Lam DC
    Lung; 2013 Dec; 191(6):645-54. PubMed ID: 23929397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
    Dziadziuszko R; Holm B; Skov BG; Osterlind K; Sellers MV; Franklin WA; Bunn PA; Varella-Garcia M; Hirsch FR
    Ann Oncol; 2007 Mar; 18(3):447-52. PubMed ID: 17082511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
    Jung M; Cho BC; Lee CH; Park HS; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Lee JH
    Yonsei Med J; 2012 Nov; 53(6):1128-35. PubMed ID: 23074112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.
    Wang F; Wang S; Wang Z; Duan J; An T; Zhao J; Bai H; Wang J;
    J Exp Clin Cancer Res; 2012 Aug; 31(1):65. PubMed ID: 22901364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.